Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Next Previous
Search
Trial Profile

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BHV-7000 (Primary)
  • Indications Bipolar disorders; Epilepsy; Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms RISE-2

    • Most Recent Events

    • 13 Apr 2024 According to Biohaven Therapeutics media release, data from the study will be presented as both oral and poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting
    • 08 Mar 2024 Status changed from not yet recruiting to recruiting.
    • 12 Jan 2024 Planned initiation date changed from 1 Dec 2023 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top